Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 12, 2016. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ordinary shares under ShareReward Plan |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.7127 per share |
| Total Volume | 14 Ordinary shares (7 partnership shares + 7 matching shares) |
| Transaction Date | July 11, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It discloses a single, routine equity compensation transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a mandatory disclosure of an insider transaction.
Key Facts for Investor Verification
- The transaction involved Mr. N Hirons, SVP of Global Ethics & Compliance.
- The acquisition was executed under the Company's ShareReward Plan.
- The total number of shares acquired was 14, split equally between partnership and matching shares.
- The transaction price of £16.7127 reflects the market price at the time of execution on the London Stock Exchange.